Virax Biolabs Group Limited
Virax Biolabs Group Limited (VRAX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
vrax · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Virax Biolabs Group LimitedYou VRAX | $1M | N/A | — | — |
 Artelo Biosciences, Inc. ARTL | $3M | N/A | — | -$5.47 |
 Avenue Therapeutics, Inc. ATXI | $1M | N/A | — | -$0.93 |
 Dermata Therapeutics, Inc. DRMA | $1M | N/A | — | -$8.16 |
 PMGC Holdings Inc. ELAB | $3M | N/A | — | -$378.74 |
 GT Biopharma, Inc. GTBP | $4M | N/A | — | -$5.14 |
 Moolec Science S.A. MLEC | $5M | N/A | — | -$258.69 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Virax Biolabs Group Limited (VRAX) measures how much investors pay for each dollar of the company's trailing earnings. VRAX's current PE ratio of N/A is calculated by dividing its stock price of $0.19 by its TTM earnings per share of —.
Frequently asked questions
VRAX pe ratio · 6 questionsVRAX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.19 and TTM EPS of —. Data sourced from Financial Modeling Prep via VRAX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Virax Biolabs Group Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09